You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTamsulosin
Accession NumberDB00706  (APRD00036)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.
Structure
Thumb
Synonyms
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
Tamsulosin
Tamsulosina
Tamsulosine
Tamsulosinum
External Identifiers
  • LY 253351
  • Y 617
  • YM 12617-1
  • YM-617
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-tamsulosin CRTablet, extended release0.4 mgOralAvanstra Inc2011-09-192014-08-21Canada
FlomaxCapsule.4 mg/1OralCardinal Health1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralLake Erie Medical DBA Quality Care Products2010-05-13Not applicableUs
FlomaxCapsule.4 mg/1Oralbryant ranch prepack1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralA S Medication Solutions Llc1999-06-03Not applicableUs
FlomaxCapsule, extended release0.4 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1998-06-192009-08-27Canada
FlomaxCapsule.4 mg/1OralSTAT Rx USA LLC1997-09-12Not applicableUs
FlomaxCapsule.4 mg/1OralPhysicians Total Care, Inc.2001-08-28Not applicableUs
FlomaxCapsule.4 mg/1OralREMEDYREPACK INC.2011-03-30Not applicableUs
Flomax CRTablet, extended release0.4 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2005-10-11Not applicableCanada
Jamp-tamsulosinCapsule, extended release0.4 mgOralJamp Pharma Corporation2010-06-162012-07-05Canada
Mylan-tamsulosinCapsule, extended release0.4 mgOralMylan Pharmaceuticals Ulc2007-08-16Not applicableCanada
Ran-tamsulosinCapsule, extended release0.4 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-08-152012-06-13Canada
Ratio-tamsulosinCapsule, extended release0.4 mgOralTeva Canada Limited2007-04-27Not applicableCanada
Sandoz TamsulosinCapsule, extended release0.4 mgOralSandoz Canada Incorporated2007-05-16Not applicableCanada
Sandoz TamsulosinCapsule, extended release0.4 mgOralSandoz Canada Incorporated2014-03-19Not applicableCanada
Sandoz Tamsulosin CRTablet, extended release0.4 mgOralSandoz Canada Incorporated2011-01-04Not applicableCanada
Tamsulosin CRTablet, extended release0.4 mgOralSanis Health Inc2014-07-24Not applicableCanada
Tamsulosin CRTablet, extended release0.4 mgOralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
Tamsulosin CRTablet, extended release0.4 mgOralPro Doc Limitee2013-11-21Not applicableCanada
Teva-tamsulosinCapsule, extended release0.4 mgOralTeva Canada Limited2007-02-21Not applicableCanada
Teva-tamsulosin CRTablet, extended release0.4 mgOralTeva Canada Limited2013-09-04Not applicableCanada
UfloCapsule, extended release0.4 mgOralTriton Pharma IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tamsulosin CRTablet, extended release0.4 mgOralApotex Inc2012-02-09Not applicableCanada
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2014-03-172016-04-05Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralBlenheim Pharmacal, Inc.2013-10-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralSun Pharmaceutical Industries Limited2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralTeva Pharmaceuticals USA Inc2010-04-272015-12-31Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2011-07-202016-10-29Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2010-03-022016-11-29Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralCardinal Health2010-10-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMed Vantx, Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralCitron Pharma LLC2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralRebel Distributors Corp2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMajor Pharmaceuticals2015-01-05Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralGolden State Medical Supply, Inc.2013-03-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralCarilion Materials Management2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralA S Medication Solutions2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2013-02-272016-04-05Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2014-04-09Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralSTAT Rx USA LLC2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralProficient Rx LP2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAmerican Health Packaging2010-10-072015-12-29Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralProficient Rx LP2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2013-04-22Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMylan Pharmaceuticals Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralWockhardt Limited2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralDispensing Solutions, Inc.2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPd Rx Pharmaceuticals, Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-02-20Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralUnit Dose Services2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPd Rx Pharmaceuticals, Inc.2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPhysicians Total Care, Inc.2010-03-10Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPar Pharmaceutical2013-03-19Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralA S Medication Solutions2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2013-07-05Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralUnit Dose Services2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2014-08-012016-04-05Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralAidarex Pharmaceuticals LLC2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1Oralbryant ranch prepack2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-07-15Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMylan Institutional Inc.2010-05-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-29Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralClinical Solutions Wholesale, Llc2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralContract Pharmacy Services Pa2010-07-28Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralWOCKHARDT USA LLC2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAurobindo Pharma Limited2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralActavis Pharma, Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule, gelatin coated.4 mg/1OralCardinal Health2010-05-10Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2013-07-25Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralDIRECT RX2015-11-25Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralMc Kesson Contract Packaging2013-05-10Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralA S Medication Solutions2013-04-30Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPreferred Pharmaceuticals, Inc2010-10-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralH.J. Harkins Company, Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralSynthon Pharmaceuticals, Inc.2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAvera Mc Kennan Hospital2015-03-31Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralA S Medication Solutions2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralSandoz Inc2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralClinical Solutions Wholesale2010-10-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralAmerican Health Packaging2014-01-17Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralCardinal Health2010-05-07Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralREMEDYREPACK INC.2011-05-182016-10-13Us
Tamsulosin HydrochlorideCapsule.4 mg/1OralCadila Healthcare Limited2010-04-27Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralPreferred Pharmaceuticals, Inc.2014-05-08Not applicableUs
Tamsulosin HydrochlorideCapsule.4 mg/1OralRed Pharm Drug, Inc.2010-04-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetamsalHemofarm
Contiflo XLRanbaxy
FlomaxtraAstellas
Harnal DAstellas
MaxrinSquare
MecirBoehringer Ingelheim
OmexelAstellas
OmiproJelfa
OmixAstellas
OmnicAstellas Pharma Europe
PradifBoehringer Ingelheim
RanomaxRanbaxy
SaloverAversi
SecotexBoehringer Ingelheim
StronazonActavis
TamsactActavis
TamsolApex
TamsulAspen Pharmacare
UrimaxCeleris
Brand mixtures
NameLabellerIngredients
Dutasteride and Tamsulosin HydrochloridePar Pharmaceutical
JalynGlaxo Smith Kline Llc
Salts
Name/CASStructureProperties
Tamsulosin Hydrochloride
ThumbNot applicableDBSALT000978
Categories
UNIIG3P28OML5I
CAS number106133-20-4
WeightAverage: 408.512
Monoisotopic: 408.171892706
Chemical FormulaC20H28N2O5S
InChI KeyDRHKJLXJIQTDTD-OAHLLOKOSA-N
InChI
InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
IUPAC Name
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide
SMILES
CCOC1=CC=CC=C1OCCN[[email protected]](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Pharmacology
IndicationUsed in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)
Structured Indications
PharmacodynamicsTamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a racemic mixture of 2 isomers, and is pharmacologically related to doxazocin, prazosin, and terazosin. However, unlike these drugs, tamsulosin has a higher affinity for the alpha-1A- adrenergic receptors, which are located in vascular smooth muscle. Studies show that tamsulosin has about 12 times greater affinity for alpha-1 adrenergic receptors in the prostate than those in the aorta, which may result in a reduced incidence of adverse cardiovascular effects.
Mechanism of actionTamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate, and thus decreases urinary outflow resistance in men.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Related Articles
AbsorptionAbsorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.
Volume of distribution
  • 16 L [intravenous administration to ten healthy male adults]
Protein binding94%-99%
Metabolism

Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established.

Route of eliminationTamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion. On administration of the radiolabeled dose of tamsulosin hydrochloride to four healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours.
Half life5-7 hours
Clearance
  • 2.88 L/h
ToxicityLD50 = 650 mg/kg (in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Tamsulosin can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Acetazolamide.Approved, Vet Approved
AdrafinilTamsulosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tamsulosin.Approved
AlfuzosinAlfuzosin may increase the antihypertensive activities of Tamsulosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Tamsulosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tamsulosin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Tamsulosin.Approved
AmiodaroneThe serum concentration of Tamsulosin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazTamsulosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineTamsulosin may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Tamsulosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.Approved, Investigational
AmrinoneTamsulosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Tamsulosin.Approved
AnisodamineTamsulosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tamsulosin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Tamsulosin.Approved
AprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineTamsulosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTamsulosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Tamsulosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tamsulosin.Approved, Investigational
ArtemetherThe metabolism of Tamsulosin can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Tamsulosin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
AtomoxetineThe metabolism of Tamsulosin can be decreased when combined with Atomoxetine.Approved
AzelnidipineTamsulosin may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tamsulosin.Approved
AzimilideTamsulosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Tamsulosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Tamsulosin.Illicit
BarnidipineTamsulosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tamsulosin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tamsulosin.Approved
BenidipineTamsulosin may increase the hypotensive activities of Benidipine.Approved
BepridilTamsulosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BexaroteneThe serum concentration of Tamsulosin can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BitolterolTamsulosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Tamsulosin can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BortezomibThe metabolism of Tamsulosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Tamsulosin can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Tamsulosin.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tamsulosin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamsulosin.Approved, Investigational
BucindololTamsulosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Tamsulosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tamsulosin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tamsulosin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
BupropionThe serum concentration of Tamsulosin can be increased when it is combined with Bupropion.Approved
CaiTamsulosin may increase the hypotensive activities of Cai.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tamsulosin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tamsulosin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tamsulosin.Approved
CarbamazepineThe metabolism of Tamsulosin can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tamsulosin.Approved
CarteololCarteolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
CarvedilolTamsulosin may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Tamsulosin can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
CeritinibThe serum concentration of Tamsulosin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Tamsulosin can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tamsulosin.Approved, Vet Approved
ChlorpromazineThe metabolism of Tamsulosin can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tamsulosin.Approved
CholecalciferolThe metabolism of Tamsulosin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tamsulosin.Approved
CilnidipineTamsulosin may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Tamsulosin can be increased when it is combined with Cinacalcet.Approved
CinnarizineTamsulosin may increase the hypotensive activities of Cinnarizine.Approved
CirazolineTamsulosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe metabolism of Tamsulosin can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Tamsulosin can be decreased when combined with Clemastine.Approved
ClenbuterolTamsulosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineTamsulosin may increase the hypotensive activities of Clevidipine.Approved
ClobazamThe metabolism of Tamsulosin can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tamsulosin.Approved, Investigational
ClomipramineThe metabolism of Tamsulosin can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tamsulosin.Approved
ClotrimazoleThe metabolism of Tamsulosin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Tamsulosin can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Tamsulosin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Tamsulosin can be increased when it is combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Tamsulosin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Tamsulosin can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Tamsulosin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.Investigational
DarifenacinThe metabolism of Tamsulosin can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineTamsulosin may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Tamsulosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Tamsulosin can be increased when it is combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tamsulosin.Approved
DesipramineThe metabolism of Tamsulosin can be decreased when combined with Desipramine.Approved
DetomidineTamsulosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Tamsulosin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tamsulosin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tamsulosin.Approved
DihydroergotamineThe metabolism of Tamsulosin can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Tamsulosin can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tamsulosin.Approved
DiphenhydramineThe metabolism of Tamsulosin can be decreased when combined with Diphenhydramine.Approved
DipivefrinTamsulosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tamsulosin.Approved
DobutamineTamsulosin may decrease the vasoconstricting activities of Dobutamine.Approved
DotarizineTamsulosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Tamsulosin.Approved
DoxycyclineThe metabolism of Tamsulosin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Tamsulosin can be decreased when combined with Dronedarone.Approved
DroxidopaTamsulosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineTamsulosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfavirenzThe serum concentration of Tamsulosin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineTamsulosin may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Tamsulosin can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tamsulosin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tamsulosin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin.Approved
EnzalutamideThe serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide.Approved
EperisoneTamsulosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineTamsulosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinephrineTamsulosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Tamsulosin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tamsulosin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tamsulosin.Approved
ErgotamineTamsulosin may decrease the vasoconstricting activities of Ergotamine.Approved
ErythromycinThe metabolism of Tamsulosin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Tamsulosin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tamsulosin.Approved
EtilefrineTamsulosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtravirineThe serum concentration of Tamsulosin can be decreased when it is combined with Etravirine.Approved
FelodipineTamsulosin may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineTamsulosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tamsulosin.Approved
FenoterolTamsulosin may decrease the vasoconstricting activities of Fenoterol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tamsulosin.Approved
FluconazoleThe metabolism of Tamsulosin can be decreased when combined with Fluconazole.Approved
FlunarizineTamsulosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Tamsulosin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolTamsulosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Tamsulosin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tamsulosin.Approved
FosphenytoinThe metabolism of Tamsulosin can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tamsulosin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tamsulosin can be increased when it is combined with Fusidic Acid.Approved
GabapentinTamsulosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilTamsulosin may increase the hypotensive activities of Gallopamil.Investigational
GuanabenzTamsulosin may decrease the vasoconstricting activities of Guanabenz.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tamsulosin.Approved, Investigational
HaloperidolThe metabolism of Tamsulosin can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tamsulosin.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Tamsulosin.Approved
HexoprenalineTamsulosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTamsulosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Tamsulosin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tamsulosin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tamsulosin.Approved
IdelalisibThe serum concentration of Tamsulosin can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tamsulosin.Approved, Investigational
ImatinibThe metabolism of Tamsulosin can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tamsulosin.Investigational
ImipramineThe metabolism of Tamsulosin can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Tamsulosin.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Tamsulosin.Withdrawn
IndinavirThe serum concentration of Tamsulosin can be increased when it is combined with Indinavir.Approved
IndoraminTamsulosin may increase the antihypertensive activities of Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tamsulosin.Approved, Investigational
IsavuconazoniumThe metabolism of Tamsulosin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tamsulosin.Approved
IsoetarineTamsulosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tamsulosin.Approved, Vet Approved
IsoniazidThe metabolism of Tamsulosin can be decreased when combined with Isoniazid.Approved
IsoprenalineTamsulosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tamsulosin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tamsulosin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Tamsulosin.Approved, Withdrawn
IsradipineThe metabolism of Tamsulosin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tamsulosin can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Tamsulosin.Approved
LacidipineTamsulosin may increase the hypotensive activities of Lacidipine.Approved
LamotrigineTamsulosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LercanidipineTamsulosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tamsulosin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tamsulosin.Approved
LevodopaTamsulosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tamsulosin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tamsulosin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Tamsulosin.Approved, Investigational
LopinavirThe serum concentration of Tamsulosin can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Tamsulosin can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tamsulosin.Approved
LovastatinThe metabolism of Tamsulosin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Tamsulosin can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Tamsulosin can be decreased when combined with Lumefantrine.Approved
Magnesium SulfateTamsulosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineTamsulosin may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Tamsulosin.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tamsulosin.Approved
MedetomidineTamsulosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineTamsulosin may decrease the vasoconstricting activities of Mephentermine.Approved
MetaraminolTamsulosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Tamsulosin can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Tamsulosin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Tamsulosin.Approved
MethotrimeprazineThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.Approved
MethoxamineTamsulosin may decrease the vasoconstricting activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tamsulosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Tamsulosin.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tamsulosin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Tamsulosin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Tamsulosin.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
MibefradilTamsulosin may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineTamsulosin may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Tamsulosin can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tamsulosin.Approved
MirabegronThe metabolism of Tamsulosin can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Tamsulosin can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Tamsulosin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tamsulosin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tamsulosin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Tamsulosin.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Tamsulosin.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
NafcillinThe serum concentration of Tamsulosin can be decreased when it is combined with Nafcillin.Approved
NaftopidilTamsulosin may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineTamsulosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Tamsulosin.Approved, Investigational
NefazodoneThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Tamsulosin.Approved, Investigational
NetupitantThe serum concentration of Tamsulosin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Tamsulosin can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Tamsulosin can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Tamsulosin.Approved
NifedipineTamsulosin may increase the hypotensive activities of Nifedipine.Approved
NiguldipineTamsulosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Tamsulosin can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineTamsulosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineTamsulosin may increase the hypotensive activities of Nilvadipine.Approved
NimesulideTamsulosin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineTamsulosin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTamsulosin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTamsulosin may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tamsulosin.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tamsulosin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tamsulosin.Approved
NorepinephrineTamsulosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NylidrinTamsulosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tamsulosin.Approved
OlaparibThe metabolism of Tamsulosin can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tamsulosin.Approved, Investigational
OlodaterolTamsulosin may decrease the vasoconstricting activities of Olodaterol.Approved
OrciprenalineTamsulosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Tamsulosin can be increased when it is combined with Osimertinib.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
OxymetazolineTamsulosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamsulosin.Approved, Vet Approved
PalbociclibThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Tamsulosin can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Tamsulosin.Approved
ParoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
PentobarbitalThe metabolism of Tamsulosin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineTamsulosin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tamsulosin.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tamsulosin.Approved
PhenobarbitalThe metabolism of Tamsulosin can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tamsulosin.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Tamsulosin.Approved
PhenylephrineTamsulosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTamsulosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Tamsulosin can be increased when combined with Phenytoin.Approved, Vet Approved
PinaveriumTamsulosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tamsulosin.Approved
PirbuterolTamsulosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PosaconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tamsulosin.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Tamsulosin.Approved
PregabalinTamsulosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineTamsulosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidoneThe metabolism of Tamsulosin can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolTamsulosin may decrease the vasoconstricting activities of Procaterol.Approved
PromazineThe metabolism of Tamsulosin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tamsulosin.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
PseudoephedrineTamsulosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tamsulosin.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tamsulosin.Approved, Investigational
QuinidineThe serum concentration of Tamsulosin can be increased when it is combined with Quinidine.Approved
QuinineThe metabolism of Tamsulosin can be decreased when combined with Quinine.Approved
RacepinephrineTamsulosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineTamsulosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tamsulosin.Approved
RanolazineThe metabolism of Tamsulosin can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tamsulosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tamsulosin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tamsulosin.Approved
RifabutinThe metabolism of Tamsulosin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Tamsulosin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tamsulosin can be increased when combined with Rifapentine.Approved
RilmenidineTamsulosin may decrease the vasoconstricting activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Tamsulosin.Approved
RisedronateTamsulosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneTamsulosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronTamsulosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTamsulosin may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Tamsulosin can be decreased when combined with Rolapitant.Approved
RomifidineTamsulosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Tamsulosin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tamsulosin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tamsulosin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tamsulosin.Approved
SalbutamolTamsulosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTamsulosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tamsulosin.Approved, Investigational, Vet Approved
SertralineThe metabolism of Tamsulosin can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tamsulosin.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
SilodosinTamsulosin may increase the antihypertensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Tamsulosin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Tamsulosin can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Tamsulosin.Approved
SolabegronTamsulosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Tamsulosin.Approved
SR 58611Tamsulosin may decrease the vasoconstricting activities of SR 58611.Investigational
St. John's WortThe serum concentration of Tamsulosin can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Tamsulosin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.Approved, Investigational
SulfisoxazoleThe metabolism of Tamsulosin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SynephrineTamsulosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TelaprevirThe serum concentration of Tamsulosin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tamsulosin.Approved, Investigational
TerazosinTamsulosin may increase the antihypertensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Tamsulosin can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTamsulosin may decrease the vasoconstricting activities of Terbutaline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Tamsulosin.Approved, Vet Approved
ThioridazineThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.Approved
TiclopidineThe metabolism of Tamsulosin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved
TipranavirThe serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tamsulosin.Approved
TocilizumabThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTamsulosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Tamsulosin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tamsulosin.Approved
TranilastTamsulosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Tamsulosin.Approved
TrimazosinTamsulosin may increase the antihypertensive activities of Trimazosin.Experimental
TulobuterolTamsulosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tamsulosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Tamsulosin.Approved
VenlafaxineThe metabolism of Tamsulosin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Tamsulosin can be decreased when combined with Verapamil.Approved
VinpocetineTamsulosin may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Voriconazole.Approved, Investigational
XylazineTamsulosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineTamsulosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Tamsulosin may decrease the vasoconstricting activities of YM-178.Investigational
ZiconotideTamsulosin may increase the hypotensive activities of Ziconotide.Approved
ZiprasidoneThe metabolism of Tamsulosin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take 30 minutes after a meal (always after the same meal). Taking the drug with food minimizes plasma levels variations.
References
Synthesis Reference

Hun Wang, Jun Park, Min Kwon, Ji Shim, Bong Lee, Hong Jeon, “Controlled release formulation of tamsulosin hydrochloride and preparation process thereof.” U.S. Patent US20050100606, issued May 12, 2005.

US20050100606
General References
  1. Dunn CJ, Matheson A, Faulds DM: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61. [PubMed:11950378 ]
  2. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ: Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs. 2002;62(1):135-67. [PubMed:11790159 ]
  3. Wilt TJ, Mac Donald R, Rutks I: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081. [PubMed:12535426 ]
External Links
ATC CodesG04CA02G04CA53G04CA52
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (248 KB)
MSDSDownload (20.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.5915
Caco-2 permeable-0.6473
P-glycoprotein substrateSubstrate0.5911
P-glycoprotein inhibitor INon-inhibitor0.5734
P-glycoprotein inhibitor IINon-inhibitor0.5522
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6012
CYP450 1A2 substrateNon-inhibitor0.7876
CYP450 2C9 inhibitorInhibitor0.5916
CYP450 2D6 inhibitorNon-inhibitor0.8614
CYP450 2C19 inhibitorNon-inhibitor0.5056
CYP450 3A4 inhibitorInhibitor0.718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6146
Ames testNon AMES toxic0.6245
CarcinogenicityNon-carcinogens0.6419
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4091 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.6971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Synthon pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral0.4 mg
CapsuleOral
Capsule, extended releaseOral
CapsuleOral.4 mg/1
Capsule, gelatin coatedOral.4 mg/1
Capsule, extended releaseOral0.4 mg
Prices
Unit descriptionCostUnit
Flomax 0.4 mg capsule4.71USD capsule
Tamsulosin hcl 0.4 mg capsule4.3USD capsule
Flomax Cr 0.4 mg Extended-Release Tablet0.63USD tablet
Mylan-Tamsulosin 0.4 mg Sustained-Release Capsule0.63USD capsule
Novo-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ran-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ratio-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Sandoz Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2144077 No2005-05-242013-09-10Canada
CA2490299 No2008-08-262023-12-24Canada
US4703063 No1993-04-272010-04-27Us
US5565467 No1995-11-202015-11-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-228 °C (HCl salt)Not Available
water solubilitySparingly soluble in waterNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP3.05ALOGPS
logP2.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)9.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity108.86 m3·mol-1ChemAxon
Polarizability43.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Amphetamine or derivatives
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96. [PubMed:9352698 ]
  3. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165 ]
  4. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700 ]
  5. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67. [PubMed:8647141 ]
  6. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54. [PubMed:8647140 ]
  7. Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. doi: 10.1016/j.mehy.2009.02.022. Epub 2009 May 8. [PubMed:19427736 ]
  8. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8. [PubMed:9117115 ]
  3. Lowe FC: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13-21. [PubMed:16986050 ]
  4. Tomiyama Y, Tatemichi S, Tadachi M, Kobayashi S, Hayashi M, Kobayashi M, Yamazaki Y, Shibata N: [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:225-30. [PubMed:16518087 ]
  5. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  6. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  7. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  2. Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719 ]
  3. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  4. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997 Sep 15;33(1):55-9. [PubMed:9294627 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Matsushima H, Watanabe T, Higuchi S: Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J Pharm Sci. 2000 Apr;89(4):490-8. [PubMed:10737910 ]
  2. Hanada K, Tochikura N, Ogata H: Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Biol Pharm Bull. 2007 Aug;30(8):1593-5. [PubMed:17666829 ]
  3. Koiso K, Akaza H, Kikuchi K, Aoyagi K, Ohba S, Miyazaki M, Ito M, Sueyoshi T, Matsushima H, Kamimura H, Watanabe T, Higuchi S: Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol. 1996 Nov;36(11):1029-38. [PubMed:8973992 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:45